Catabasis’ PolarisDMD clinical trial for edasalonexent completes enrollment
US biopharma company Catabasis Pharmaceuticals has wrapped up enrollment for the phase 3 PolarisDMD clinical trial designed to evaluate edasalonexent, an NF-kB inhibitor, in Duchenne muscular dystrophy (DMD). The biopharma company said that the target enrollment of 125 boys was surpassed owing to strong interest from its 40 clinical sites across eight countries along with […]